rewirebio.iobenchmarks
Evidence and investigation

Contested results

Where one study disagrees with what other studies report for the same models, and what we are doing to resolve each case.

These are automatic leads, not findings of error. Each release, a check compares how every study ranks the models it shares with other studies. It flags a study that reverses the order the others agree on, or whose gap to a shared reference model lies well outside theirs. Different tasks, populations or metrics often explain a flag.

A flag never hides a result. Flagged results stay in every table, page and download, marked Contested. A result is withheld only when a reviewer marks it disputed.

How the check works, and how each follow-up is recorded: discrepancies between studies.

In this release

  • 192open
  • 6settled
  • 7resolved
  • 3medium severity
  • 202low severity

Release 2026-11-21-adc15377fab2 · 205 findings in all · rules version 5

Findings

Status: All · Open · Settled · Resolved

Severity: All · Medium · Low

State: All · Not yet reviewed · Under investigation · Explained · Confirmed error · Not a real disagreement

Showing findings that involve results in Interpret BRCA1/BRCA2 germline variants, from the study that disagrees or from the agreeing group. All use cases

2 findings match, most severe first.

Eigen and MutationAssessor: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) reverses the order

  • Low severity
  • Explained
  • Ordering reversal
  • unknown

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks MutationAssessor above Eigen in 6 of 7 comparisons; 3 of 3 other studies rank Eigen above MutationAssessor.

3 papers rank Eigen above MutationAssessor in 17 of their 22 comparisons and MutationAssessor higher in 1; 4 are ties. Livesey and Marsh 2025 ranks MutationAssessor above Eigen in 6 of its 7 comparisons and Eigen higher in 1.

Comparisons in which each paper scores Eigen or MutationAssessor higher3 other papers: Eigen higher in 17, MutationAssessor higher in 1, 4 ties. Livesey and Marsh 2025 (disagrees): Eigen higher in 1, MutationAssessor higher in 6, 0 ties.3 other papers17 Eigen higher174 tie41 MutationAssessor higherDisagrees: Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)1 Eigen higher16 MutationAssessor higher6
Eigen higherTieMutationAssessor higher
Compared
Eigen, MutationAssessor

1 follow-up action, latest 23 October 2026

ESM-1b and EVE: Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods reverses the order

  • Low severity
  • Explained
  • Ordering reversal
  • Same task, different protocols

Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods ranks ESM-1b above EVE in 6 of 6 comparisons; 2 of 2 other studies rank EVE above ESM-1b.

2 papers rank EVE above ESM-1b in 22 of their 26 comparisons and ESM-1b higher in 1; 3 are ties. Brandes et al. 2023 ranks ESM-1b above EVE in all 6 comparisons that are not ties (2 are ties).

Comparisons in which each paper scores EVE or ESM-1b higher2 other papers: EVE higher in 22, ESM-1b higher in 1, 3 ties. Brandes et al. 2023 (disagrees): EVE higher in 0, ESM-1b higher in 6, 2 ties.2 other papers22 EVE higher223 tie31 ESM-1b higherDisagrees: Brandes et al. 2023Brandes et al. 2023 Supplementary Table 2: full benchmark evaluations of ESM1b and all other methods2 tie26 ESM-1b higher6
EVE higherTieESM-1b higher
Compared
ESM-1b, EVE

3 follow-up actions, latest 21 November 2026